TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 335912
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg orally twice daily for 1 week)
Study: 335912
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and Pilocarpine (combined treatment)
Study: 31410787
Drug: Peficitinib 100
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 100 mg once daily
Study: 29917064
Drug: Peficitinib 150
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 150 mg once daily
Study: 17051978
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution (A group)
Study: 17051978
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution (S group)
Study: 3435099
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg
Study: 29303025
Drug: Maternal 25(OH)D
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal 25(OH)D < 75 nmol/L during pregnancy
Study: 29303025
Drug: Maternal 25(OH)D
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal 25(OH)D ≥ 75 nmol/L during pregnancy
Study: 24888230
Drug: Ombrabulin 35
Normalized name: Ombrabulin
DrugBank: Ombrabulin (DB12882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin 35 mg/m²
Study: 22257576
Drug: Estradiol‐Depot 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol‐Depot 10 mg® (test)
Study: 28968759
Drug: PENNVAX-G DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENNVAX-G DNA delivered intramuscularly by Biojector
Study: 28968759
Drug: PENNVAX-G DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENNVAX-G DNA delivered intramuscularly by CELLECTRA electroporation device
Study: 28968759
Drug: PENNVAX-G DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENNVAX-G DNA followed by MVA-CMDR boost
Study: 17234439
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid injection
Study: 7956552
Drug: MOM nutrient
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MOM nutrient powder (30 g/day)
Study: 2892349
Drug: Ritanserin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin, 10 mg b.i.d.
Study: 31988102
Drug: Linezolid 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 1,200 mg QD
Study: 31988102
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg BD
Study: 31988102
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg QD
Study: 31988102
Drug: Linezolid 300
Normalized name: linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 300 mg BD
Study: 31988102
Drug: Linezolid 300
Normalized name: linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 300 mg QD
Study: 31988102
Drug: Linezolid 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 1,200 mg TIW
Study: 31988102
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isoniazid, rifampin, pyrazinamide, and ethambutol
Study: 27903518
Drug: LOW PRO
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW PRO diet (0.7 g · kg‐1 · d‐1)
Study: 27903518
Drug: HIGH PRO
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH PRO diet (1.5 g · kg‐1 · d‐1)
Study: 25612882
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of raw flaxseed powder every day for 40 days
Study: 7465620
Drug: Fluori‐Methane spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluori‐Methane spray and static passive stretch
Study: 18201582
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of telmisartan 40 mg + amlodipine 5 mg (T+A)
Study: 18201582
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg monotherapy (A)
Study: 14504682
Drug: Sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-200 mg once daily)
Study: 7840861
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tropisetron
Study: 3048759
Drug: Amodiaquine (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (1800 mg for 3 days)
Study: 3048759
Drug: Sulfadoxine-pyrimethamine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (1500 mg and 75 mg, respectively)
Study: 31128268
Drug: Citalopram (CTP)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CTP) adjunctive to methylphenidate (MPH)
Study: 31128268
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) adjunctive to methylphenidate (MPH)
Study: 28800778
Drug: Individualized PEEP
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized PEEP values determined during a static pulmonary compliance (Cstat)‐directed PEEP titration procedure
Study: 20835903
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rejection of ASV treatment or usage <50% of nights possible and/or <4 h/night; n = 59)
Study: 17157757
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (3000 mg/day)
Study: 9065092
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine instillations (1 mg, annual scheme)
Study: 9065092
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 patients without bladder cancer and without vaccine instillations)
Study: 3971650
Drug: Intravenous flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flecainide (2 mg/kg)
Study: 23394517
Drug: Flupirtine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (200 mg p.o.)
Study: 17197840
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (1.5 mg/kg bolus at induction, 2 mg/kg/h intraoperatively, 1.33 mg/kg/h for 24 h postoperatively)
Study: 9727072
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (Premarin 1.25 mg)
Study: 9727072
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (Estraderm 100TTS)
Study: 7775623
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and transdermal estrogen
Study: 23280269
Drug: Robotic-assisted home
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted home therapy
Study: 17021714
Drug: Dipyridamole 400
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole 400 mg/day
Study: 9291301
Drug: Serotype G1
Normalized name: Rotavirus serotype G1 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype G1 monovalent vaccine
Study: 9291301
Drug: Serotype G1‐G4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype G1‐G4 tetravalent vaccine
Study: 3792434
Drug: Ciramadol 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol 15 mg
Study: 29667496
Drug: INT-SIT (sitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: INT-SIT (sitting interrupted hourly with 20 min light-intensity treadmill desk walking at 1.2-3.5 km/h)
Study: 27043671
Drug: Olmesartan/amlodipine fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/amlodipine fixed combination 20/5mg
Study: 24018781
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg
Study: 22707251
Drug: Nicotine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (4 mg via gum)
Study: 17852806
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day for 5 days
Study: 17852806
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg three times a day for 4 days and a single dose on day 5
Study: 17852806
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 4 days and a single dose on day 5 (control for indomethacin)
Study: 15819388
Drug: Isosorbide-5-mononitrate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (10 mg)
Study: 15819388
Drug: Bisoprolol fumarate
Normalized name: Bisoprolol Fumarate
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol fumarate (5 mg)
Study: 15819388
Drug: Nisoldipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (5 mg)
Study: 8555143
Drug: Implant-retained mandibular
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained mandibular overdentures and a new maxillary denture
Study: 2289472
Drug: Clonazepam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (4.5 mg)
Study: 31589323
Drug: Lorcaserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin (10 mg twice daily) plus nicotine patch (21 mg)
Study: 31589323
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nicotine patch (21 mg)
Study: 31765422
Drug: Community based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community based health education provided by community health volunteers (CHVs) with weekly supplements and follow-ups.
Study: 17419678
Drug: EPF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPF treatment (60 mg Icariin, 15 mg Daidzein, and 3 mg Genistein daily)
Study: 20336635
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (ET)
Study: 10365355
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 2 mg 4 mL-1, 12 hourly (maximum four doses)
Study: 10365355
Drug: Placebo, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 12 hourly (maximum four doses)
Study: 2285296
Drug: Intravenous chloramphenicol
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous chloramphenicol succinate
Study: 2285296
Drug: Oral chloramphenicol
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloramphenicol capsules
Study: 7033352
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g, four times daily)
Study: 27798022
Drug: Parenting Acceptance
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenting Acceptance and Commitment Therapy (PACT)
Study: 31479745
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy Defibrillator (CRT‐D) implantation
Study: 21792642
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) - low exposure (<1,500 mg average daily dose)
Study: 21792642
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) - high exposure (≥1,500 mg average daily dose)
Study: 21792642
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) - any exposure (<1,500 or ≥1,500 average daily dose)
Study: 24122181
Drug: Quinacrine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinacrine (300 mg daily)
Study: 19278902
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (random assignment)
Study: 17140572
Drug: P and
Normalized name: P and S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P and 4 mg E(2) orally (n = 54)
Study: 9690055
Drug: Intensive subcutaneous
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive subcutaneous insulin therapy for about 12 days in a subgroup of 7 diabetic subjects
Study: 30973970
Drug: Oral navoximod
Normalized name: Navoximod
DrugBank: Navoximod (DB15439)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral navoximod (200 mg tablet)
Study: 30973970
Drug: Intravenous navoximod
Normalized name: Navoximod
DrugBank: Navoximod (DB15439)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous navoximod (5 mg solution)
Study: 30973970
Drug: [14C]‐navoximod (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: [14C]‐navoximod (200 mg/600 μCi) as an oral solution
Study: 30973970
Drug: Navoximod (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navoximod (200 mg)
Study: 12914803
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive therapy
Study: 24281563
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBTG)
Study: 17324239
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN (0.6 mg h(‐1) for 2 h, administered 24 h before IR)
Study: 17324239
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g i.v. at the time of GTN administration) + GTN
Study: 17324239
Drug: Ciclosporin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (100 mg 2 h prior to GTN administration) + GTN
Study: 14735403
Drug: Staphylococcal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staphylococcal vaccine (Staphypan Berna)
Study: 11680551
Drug: Age, gender,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, gender, gender match, experience with cognitive-behavioral therapy (CBT)
Study: 9137231
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of omega-3 fatty acids daily
Study: 2444961
Drug: Verapamil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil infusion at 5 mg/h
Study: 2444961
Drug: Elemental calcium
Normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental calcium infusion at 3 mg/kg over 10 minutes
Study: 29397432
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy (18 days of standardised treatment combining thermal therapy and supervised mobilisation in a thermal pool)
Study: 29397432
Drug: Control (spa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (spa therapy delayed for 6 months)
Study: 23591294
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg · kg(‐1)
Study: 15845797
Drug: 0.3 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mmol/kg gadolinium dose
Study: 15845797
Drug: 0.4 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mmol/kg gadolinium dose
Study: 10229291
Drug: Lipid lowering
Normalized name: Lipid lowering agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid lowering therapy according to SMAC guidelines
Study: 8671425
Drug: HP-FSH (highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-FSH (highly purified follicle stimulating hormone)
Study: 31409394
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PD-1 and CTLA-4 inhibition, tumor-directed radiation, cyclophosphamide (CTX), and L-n6-(1-iminoethyl)-lysine (L-NIL)
Study: 31409394
Drug: PD-1 and
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 and CTLA-4 blockade, and radiotherapy alone or in combination
Study: 31409394
Drug: CTX/L-NIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX/L-NIL
Study: 29482797
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of auricular and systemic acupuncture (GIII)
Study: 22989819
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg) plus Hydrochlorothiazide (12.5 mg)
Study: 20589313
Drug: ARC1779 (4-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARC1779 (4-5 microg/ml)
Study: 20589313
Drug: ARC1779 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARC1779 and desmopressin combination
Study: 17386345
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g) and Vitamin E (400 IU)
Study: 9693397
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 0.02 mg ethinyl estradiol and 0.15 mg desogestrel (preparation A)
Study: 9693397
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 0.03 mg ethinyl estradiol and 2.00 mg dienogest (preparation B)
Study: 3277153
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of therapy with cefaclor (40 mg/kg/day)
Study: 3277153
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of therapy with cefaclor (40 mg/kg/day)
Study: 3277153
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days vs 10 days of therapy
Study: 31210529
Drug: Ipragliflozin 50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 50 mg/day
Study: 30821047
Drug: Ipragliflozin 100
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 100 mg/day
Study: 27495072
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided split injection technique for rectus sheath block (RSB group, n=20)
Study: 20650049
Drug: Test formulation:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation: escitalopram (10 mg tablet) manufactured by Apsen Farmacêutica S.A.
Study: 20650049
Drug: Reference formulation:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation: escitalopram (Lexapro; 10 mg tablet) from Lundbeck Brasil Ltda
Study: 16088856
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for women with CMI
Study: 16088856
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for women without CMI
Study: 1875542
Drug: 1% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% mepivacaine and buprenorphine 0.2 mg (48 ml.hr‐1)
Study: 1875542
Drug: 1% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% mepivacaine and buprenorphine 0.4 mg (48 ml.hr‐1)
Study: 1875542
Drug: saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline and buprenorphine 0.2 mg (48 ml.hr‐1)
Study: 1875542
Drug: saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline and buprenorphine 0.4 mg (48 ml.hr‐1)
Study: 6981522
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 g erythromycin ethyl succinate granules twice daily orally for 10 days)
Study: 29195188
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Behavioral Therapy (ICBT)
Study: 29195188
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioral Therapy (GCBT)
Study: 24727078
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) combined (ICBT and GCBT)
Study: 21901395
Drug: Adjuvant anthracycline-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant anthracycline-based dose-dense sequential chemotherapy
Study: 21901395
Drug: Adjuvant anthracycline-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant anthracycline-based dose-dense sequential chemotherapy with paclitaxel
Study: 20813593
Drug: Cefazedone 500
Normalized name: cefazedone
DrugBank: Cefazedone (DB13778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazedone 500 mg IV
Study: 20813593
Drug: Cefazedone 1000
Normalized name: cefazedone
DrugBank: Cefazedone (DB13778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazedone 1000 mg IV
Study: 20813593
Drug: Cefazedone 2000
Normalized name: cefazedone
DrugBank: Cefazedone (DB13778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazedone 2000 mg IV
Study: 15923569
Drug: Carboxyaminoimidazole (CAI)
Normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxyaminoimidazole (CAI) 250 mg/d
Study: 9809381
Drug: Creatine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (15 g/d)
Study: 9809381
Drug: Creatine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (2 g/d)
Study: 8430713
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 to 20 mg)
Study: 8430713
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 100 mg)
Study: 24944041
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg/day for 7 days) with PF-04449913 (200 mg single dose on day 4)